Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
UTHR's Cash-to-Debt is ranked higher than
94% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 59.90 vs. UTHR: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
UTHR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.91  Med: 22.67 Max: No Debt
Current: No Debt
Equity-to-Asset 0.80
UTHR's Equity-to-Asset is ranked higher than
68% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. UTHR: 0.80 )
Ranked among companies with meaningful Equity-to-Asset only.
UTHR' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.43  Med: 0.73 Max: 0.94
Current: 0.8
0.43
0.94
Interest Coverage 272.23
UTHR's Interest Coverage is ranked lower than
67% of the 484 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. UTHR: 272.23 )
Ranked among companies with meaningful Interest Coverage only.
UTHR' s Interest Coverage Range Over the Past 10 Years
Min: 2.02  Med: 16.2 Max: 272.23
Current: 272.23
2.02
272.23
Piotroski F-Score: 6
Altman Z-Score: 12.61
Beneish M-Score: -2.10
WACC vs ROIC
12.59%
92.78%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 66.41
UTHR's Operating Margin % is ranked higher than
98% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -88.13 vs. UTHR: 66.41 )
Ranked among companies with meaningful Operating Margin % only.
UTHR' s Operating Margin % Range Over the Past 10 Years
Min: -29.15  Med: 35.36 Max: 66.41
Current: 66.41
-29.15
66.41
Net Margin % 44.64
UTHR's Net Margin % is ranked higher than
96% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. UTHR: 44.64 )
Ranked among companies with meaningful Net Margin % only.
UTHR' s Net Margin % Range Over the Past 10 Years
Min: -17.52  Med: 22.13 Max: 44.64
Current: 44.64
-17.52
44.64
ROE % 40.57
UTHR's ROE % is ranked higher than
97% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: -34.32 vs. UTHR: 40.57 )
Ranked among companies with meaningful ROE % only.
UTHR' s ROE % Range Over the Past 10 Years
Min: -11.59  Med: 19.34 Max: 46.03
Current: 40.57
-11.59
46.03
ROA % 31.94
UTHR's ROA % is ranked higher than
98% of the 972 Companies
in the Global Biotechnology industry.

( Industry Median: -30.23 vs. UTHR: 31.94 )
Ranked among companies with meaningful ROA % only.
UTHR' s ROA % Range Over the Past 10 Years
Min: -6.75  Med: 12.09 Max: 32.03
Current: 31.94
-6.75
32.03
ROC (Joel Greenblatt) % 203.17
UTHR's ROC (Joel Greenblatt) % is ranked higher than
96% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. UTHR: 203.17 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
UTHR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -43.1  Med: 79.54 Max: 215.37
Current: 203.17
-43.1
215.37
3-Year Revenue Growth Rate 17.60
UTHR's 3-Year Revenue Growth Rate is ranked higher than
71% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. UTHR: 17.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
UTHR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 17.6  Med: 37.8 Max: 260.9
Current: 17.6
17.6
260.9
3-Year EBITDA Growth Rate 56.00
UTHR's 3-Year EBITDA Growth Rate is ranked higher than
83% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. UTHR: 56.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
UTHR' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -56.2  Med: 22.7 Max: 128
Current: 56
-56.2
128
3-Year EPS without NRI Growth Rate 66.90
UTHR's 3-Year EPS without NRI Growth Rate is ranked higher than
83% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: -3.10 vs. UTHR: 66.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
UTHR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -50.7  Med: 19.7 Max: 153.6
Current: 66.9
-50.7
153.6
GuruFocus has detected 1 Warning Sign with United Therapeutics Corp $UTHR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» UTHR's 10-Y Financials

Financials (Next Earnings Date: 2017-02-24)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

UTHR Guru Trades in Q1 2016

David Dreman 125 sh (New)
Ray Dalio 85,833 sh (+204.79%)
Lee Ainslie 20,930 sh (+98.01%)
Paul Tudor Jones 4,600 sh (+58.62%)
Joel Greenblatt 362,565 sh (+10.43%)
George Soros Sold Out
Ken Fisher 3,092 sh (-1.43%)
Jim Simons 474,578 sh (-14.04%)
» More
Q2 2016

UTHR Guru Trades in Q2 2016

David Dreman 2,670 sh (+2036.00%)
Lee Ainslie 26,710 sh (+27.62%)
Joel Greenblatt 367,075 sh (+1.24%)
Ken Fisher 3,092 sh (unchged)
Jim Simons 404,300 sh (-14.81%)
Paul Tudor Jones 3,700 sh (-19.57%)
Ray Dalio 64,100 sh (-25.32%)
» More
Q3 2016

UTHR Guru Trades in Q3 2016

Paul Tudor Jones 10,104 sh (+173.08%)
Ray Dalio 113,805 sh (+77.54%)
Ken Fisher 3,124 sh (+1.03%)
David Dreman 2,670 sh (unchged)
Lee Ainslie 25,910 sh (-3.00%)
Jim Simons 390,100 sh (-3.51%)
Joel Greenblatt 317,358 sh (-13.54%)
» More
Q4 2016

UTHR Guru Trades in Q4 2016

Jim Simons 421,200 sh (+7.97%)
Lee Ainslie 26,210 sh (+1.16%)
Ken Fisher 3,124 sh (unchged)
Joel Greenblatt 166,025 sh (-47.69%)
Ray Dalio 43,905 sh (-61.42%)
Paul Tudor Jones 3,534 sh (-65.02%)
David Dreman 146 sh (-94.53%)
» More
» Details

Insider Trades

Latest Guru Trades with UTHR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:EXEL, NAS:JAZZ, NAS:ALKS, NAS:IONS, NAS:SGEN, NAS:ACAD, NAS:ARIA, NAS:TSRO, NAS:TECH, NAS:ALNY, NAS:GLPG, NAS:ICPT, NAS:RARE, NAS:CBPO, NAS:CLVS, NAS:BLUE, NYSE:XON, NAS:KITE, OTCPK:BTGGF, OTCPK:NVZMY » details
Traded in other countries:UTH.Germany,
United Therapeutics Corp is a biotechnology company. The Company is engaged in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.

United Therapeutics Corp was incorporated in Delaware in June 1996. It is a biotechnology company. The Company is engaged in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions. Its key therapeutic products and product candidates include: Prostacyclin Analogues, Prostacyclin analogues are stable synthetic forms of prostacyclin, an important molecule produced by the body that has powerful effects on blood vessel health and function. Its product is Remodulin (treprostinil) Injection (Remodulin), which is administered under the skin or in the vein for the treatment of pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise. Phosphodiesterase Type 5 (PDE-5) Inhibitor act to inhibit the degradation of cyclic guanosine monophosphate n cells. Cyclic GMP is activated by nitric oxide (NO), a naturally occurring substance in the body that mediates the relaxation of vascular smooth muscle. Monoclonal Antibody (MAb), MAbs act by targeting tumor-associated antigens located on the surfaces of cancer cells to activate a patient's immune system against the cancer cells. Glycobiology Antiviral Agents, Glycobiology antiviral agents are a novel class of small, sugar-like molecules that have shown preclinical indications of efficacy against a broad range of viruses. Cell-Based Therapy,iIn 2011, the Company entered into a license agreement with Pluristem Ltd. (Pluristem) to develop and commercialize its cell-based product known as PLacental eXpanded (PLX) cells for the treatment of PAH. Lung transplantation, the Company is engaged in developing engineered lungs and lung tissue for transplant into patients suffering from PAH and other lung diseases. The Company competes with a number of approved products which include: Flolan, Ventavis, Ilomedin, Tracleer, Revatio, Letairis, Veletri, Adempas, Opsumit, generic epoprostenol and generic sildenafil citrate. The Company's operations must comply with extensive laws and regulations in the United States and other countries, including FDA regulations.

Top Ranked Articles about United Therapeutics Corp

Gurus Invest in Top Biotechnology Stocks Graham’s Lost Formula unearths biotech gem; many guru buys occur
Throughout the first quarter, many gurus have increased their positions in top-performing biotechnology stocks, suggesting that the biotechnology sector contains some hot opportunities to increase portfolio returns. One of the hottest biotech stocks, United Therapeutics Corp. (NASDAQ:UTHR), is currently owned by seven gurus. Additionally, four gurus increased their position in United Therapeutics, one of eight biotechnology stocks listed on the Ben Graham’s Lost Formula I Screener. Read more...

Ratios

vs
industry
vs
history
PE Ratio 9.63
UTHR's PE Ratio is ranked higher than
83% of the 277 Companies
in the Global Biotechnology industry.

( Industry Median: 27.60 vs. UTHR: 9.63 )
Ranked among companies with meaningful PE Ratio only.
UTHR' s PE Ratio Range Over the Past 10 Years
Min: 4.95  Med: 22.47 Max: 171.34
Current: 9.63
4.95
171.34
Forward PE Ratio 9.15
UTHR's Forward PE Ratio is ranked higher than
84% of the 75 Companies
in the Global Biotechnology industry.

( Industry Median: 19.72 vs. UTHR: 9.15 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 9.63
UTHR's PE Ratio without NRI is ranked higher than
84% of the 251 Companies
in the Global Biotechnology industry.

( Industry Median: 27.87 vs. UTHR: 9.63 )
Ranked among companies with meaningful PE Ratio without NRI only.
UTHR' s PE Ratio without NRI Range Over the Past 10 Years
Min: 4.95  Med: 22.42 Max: 171.34
Current: 9.63
4.95
171.34
Price-to-Owner-Earnings 11.87
UTHR's Price-to-Owner-Earnings is ranked higher than
66% of the 143 Companies
in the Global Biotechnology industry.

( Industry Median: 29.18 vs. UTHR: 11.87 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
UTHR' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.08  Med: 34.57 Max: 570.89
Current: 11.87
5.08
570.89
PB Ratio 3.72
UTHR's PB Ratio is ranked lower than
53% of the 1106 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. UTHR: 3.72 )
Ranked among companies with meaningful PB Ratio only.
UTHR' s PB Ratio Range Over the Past 10 Years
Min: 2.01  Med: 3.93 Max: 10.39
Current: 3.72
2.01
10.39
PS Ratio 4.33
UTHR's PS Ratio is ranked higher than
71% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: 12.50 vs. UTHR: 4.33 )
Ranked among companies with meaningful PS Ratio only.
UTHR' s PS Ratio Range Over the Past 10 Years
Min: 2.88  Med: 5.6 Max: 13.37
Current: 4.33
2.88
13.37
Price-to-Free-Cash-Flow 11.47
UTHR's Price-to-Free-Cash-Flow is ranked higher than
59% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 22.44 vs. UTHR: 11.47 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
UTHR' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.78  Med: 19.95 Max: 618.25
Current: 11.47
9.78
618.25
Price-to-Operating-Cash-Flow 10.72
UTHR's Price-to-Operating-Cash-Flow is ranked higher than
62% of the 204 Companies
in the Global Biotechnology industry.

( Industry Median: 21.56 vs. UTHR: 10.72 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
UTHR' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 8.33  Med: 17.39 Max: 46.12
Current: 10.72
8.33
46.12
EV-to-EBIT 5.20
UTHR's EV-to-EBIT is ranked higher than
77% of the 284 Companies
in the Global Biotechnology industry.

( Industry Median: 19.01 vs. UTHR: 5.20 )
Ranked among companies with meaningful EV-to-EBIT only.
UTHR' s EV-to-EBIT Range Over the Past 10 Years
Min: -31.2  Med: 13.05 Max: 120.9
Current: 5.2
-31.2
120.9
EV-to-EBITDA 5.06
UTHR's EV-to-EBITDA is ranked higher than
78% of the 307 Companies
in the Global Biotechnology industry.

( Industry Median: 19.22 vs. UTHR: 5.06 )
Ranked among companies with meaningful EV-to-EBITDA only.
UTHR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -33.7  Med: 12.25 Max: 102.2
Current: 5.06
-33.7
102.2
PEG Ratio 0.29
UTHR's PEG Ratio is ranked higher than
93% of the 98 Companies
in the Global Biotechnology industry.

( Industry Median: 2.11 vs. UTHR: 0.29 )
Ranked among companies with meaningful PEG Ratio only.
UTHR' s PEG Ratio Range Over the Past 10 Years
Min: 0.15  Med: 0.42 Max: 2.43
Current: 0.29
0.15
2.43
Shiller PE Ratio 29.68
UTHR's Shiller PE Ratio is ranked higher than
69% of the 55 Companies
in the Global Biotechnology industry.

( Industry Median: 47.42 vs. UTHR: 29.68 )
Ranked among companies with meaningful Shiller PE Ratio only.
UTHR' s Shiller PE Ratio Range Over the Past 10 Years
Min: 22.64  Med: 48.56 Max: 679.13
Current: 29.68
22.64
679.13
Current Ratio 4.29
UTHR's Current Ratio is ranked higher than
52% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. UTHR: 4.29 )
Ranked among companies with meaningful Current Ratio only.
UTHR' s Current Ratio Range Over the Past 10 Years
Min: 0.98  Med: 5.16 Max: 19.33
Current: 4.29
0.98
19.33
Quick Ratio 3.98
UTHR's Quick Ratio is ranked higher than
52% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 3.91 vs. UTHR: 3.98 )
Ranked among companies with meaningful Quick Ratio only.
UTHR' s Quick Ratio Range Over the Past 10 Years
Min: 0.9  Med: 4.91 Max: 19.08
Current: 3.98
0.9
19.08
Days Inventory 452.26
UTHR's Days Inventory is ranked lower than
93% of the 439 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. UTHR: 452.26 )
Ranked among companies with meaningful Days Inventory only.
UTHR' s Days Inventory Range Over the Past 10 Years
Min: 118.32  Med: 167.09 Max: 455.12
Current: 452.26
118.32
455.12
Days Sales Outstanding 48.97
UTHR's Days Sales Outstanding is ranked higher than
59% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. UTHR: 48.97 )
Ranked among companies with meaningful Days Sales Outstanding only.
UTHR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 36.71  Med: 45.68 Max: 49.96
Current: 48.97
36.71
49.96
Days Payable 40.67
UTHR's Days Payable is ranked lower than
99.99% of the 396 Companies
in the Global Biotechnology industry.

( Industry Median: 57.94 vs. UTHR: 40.67 )
Ranked among companies with meaningful Days Payable only.
UTHR' s Days Payable Range Over the Past 10 Years
Min: 18.67  Med: 40.17 Max: 246.85
Current: 40.67
18.67
246.85

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 2.40
UTHR's 3-Year Average Share Buyback Ratio is ranked higher than
99% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. UTHR: 2.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
UTHR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -9.9  Med: -0.85 Max: 4.3
Current: 2.4
-9.9
4.3

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 11.91
UTHR's Price-to-Net-Cash is ranked lower than
73% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: 5.89 vs. UTHR: 11.91 )
Ranked among companies with meaningful Price-to-Net-Cash only.
UTHR' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.51  Med: 14.77 Max: 113.59
Current: 11.91
1.51
113.59
Price-to-Net-Current-Asset-Value 7.22
UTHR's Price-to-Net-Current-Asset-Value is ranked lower than
62% of the 879 Companies
in the Global Biotechnology industry.

( Industry Median: 5.57 vs. UTHR: 7.22 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
UTHR' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.46  Med: 10.7 Max: 226.58
Current: 7.22
1.46
226.58
Price-to-Tangible-Book 3.78
UTHR's Price-to-Tangible-Book is ranked higher than
54% of the 1015 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. UTHR: 3.78 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
UTHR' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.16  Med: 4.33 Max: 14.47
Current: 3.78
1.16
14.47
Price-to-Intrinsic-Value-Projected-FCF 1.04
UTHR's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
83% of the 174 Companies
in the Global Biotechnology industry.

( Industry Median: 3.31 vs. UTHR: 1.04 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
UTHR' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.02  Med: 2.92 Max: 24.51
Current: 1.04
1.02
24.51
Price-to-Median-PS-Value 0.77
UTHR's Price-to-Median-PS-Value is ranked higher than
57% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. UTHR: 0.77 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
UTHR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.56  Med: 1.47 Max: 209.09
Current: 0.77
0.56
209.09
Price-to-Peter-Lynch-Fair-Value 0.39
UTHR's Price-to-Peter-Lynch-Fair-Value is ranked higher than
94% of the 72 Companies
in the Global Biotechnology industry.

( Industry Median: 1.56 vs. UTHR: 0.39 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
UTHR' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.38  Med: 0.91 Max: 5.77
Current: 0.39
0.38
5.77
Price-to-Graham-Number 1.27
UTHR's Price-to-Graham-Number is ranked higher than
70% of the 229 Companies
in the Global Biotechnology industry.

( Industry Median: 2.38 vs. UTHR: 1.27 )
Ranked among companies with meaningful Price-to-Graham-Number only.
UTHR' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.02  Med: 2.34 Max: 6.1
Current: 1.27
1.02
6.1
Earnings Yield (Greenblatt) % 19.20
UTHR's Earnings Yield (Greenblatt) % is ranked higher than
94% of the 1203 Companies
in the Global Biotechnology industry.

( Industry Median: -9.03 vs. UTHR: 19.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
UTHR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.8  Med: 6 Max: 40.2
Current: 19.2
0.8
40.2
Forward Rate of Return (Yacktman) % 37.32
UTHR's Forward Rate of Return (Yacktman) % is ranked higher than
84% of the 122 Companies
in the Global Biotechnology industry.

( Industry Median: 15.82 vs. UTHR: 37.32 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
UTHR' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -1.4  Med: 1.3 Max: 56.9
Current: 37.32
-1.4
56.9

More Statistics

Revenue (TTM) (Mil) $1,599
EPS (TTM) $ 15.22
Beta1.35
Short Percentage of Float15.43%
52-Week Range $97.52 - 169.89
Shares Outstanding (Mil)44.96

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 1,727 1,576 1,574
EPS ($) 15.65 15.47 14.60
EPS without NRI ($) 15.65 15.47 14.60
EPS Growth Rate
(Future 3Y To 5Y Estimate)
0.49%
Dividends per Share ($)
» More Articles for UTHR

Headlines

Articles On GuruFocus.com
Gurus Invest in Undervalued Biotech Stocks Nov 25 2016 
6 Undervalued Stocks Trading Below the Peter Lynch Value Oct 26 2016 
These Five Stocks Show a Combination of Value and Growth Aug 03 2016 
Worst Performance YTD: MasterCard, Lazard Aug 03 2016 
5 Mid-Cap Stocks With Low Enterprise Multiples Aug 03 2016 
10 Biotech and Specialty Pharma Bargains: Do You Have the Guts to Speculate? Jul 01 2016 
Gurus Invest in Top Biotechnology Stocks Jun 20 2016 
United Therapeutics Is a Value Investor's Biotech Dream Apr 28 2016 
Cummins and Deckers are Candidates for a January Bounce Nov 20 2015 
Estimated Revenue Up 5% Stock Screen Nov 18 2015 

More From Other Websites
United Therapeutics feels squeeze from increased pulmonary hypertension competition Feb 23 2017
United Therapeutics Corp. :UTHR-US: Earnings Analysis: 2016 By the Numbers : February 23, 2017 Feb 23 2017
United Therapeutics downgraded by Ladenburg Thalmann Feb 23 2017
United Therapeutics Corp. :UTHR-US: Earnings Analysis: Q4, 2016 By the Numbers : February 23, 2017 Feb 23 2017
United Therapeutics (UTHR) Down on Q4 Earnings & Sales Miss Feb 23 2017
United Therapeutics Corp Earnings Call scheduled for 9:00 am ET today Feb 22 2017
United Therapeutics beats 4Q profit forecasts Feb 22 2017
United Therapeutics beats 4Q profit forecasts Feb 22 2017
UNITED THERAPEUTICS CORP Files SEC form 8-K, Results of Operations and Financial Condition Feb 22 2017
UNITED THERAPEUTICS CORP Files SEC form 10-K, Annual Report Feb 22 2017
6:04 am United Therapeutics beats by $0.26, misses on revs Feb 22 2017
United Therapeutics Corporation Reports 2016 Fourth Quarter And Annual Financial Results Feb 22 2017
United Therapeutics Corporation To Report Fourth Quarter And Annual 2016 Financial Results Before... Feb 15 2017
Your Guide To 2017's Emerging Pharmaceuticals Catalysts Feb 07 2017
UNITED THERAPEUTICS CORP Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in... Feb 03 2017
UNITED THERAPEUTICS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of... Jan 30 2017
D.C.-area biotech stocks fall on Trump's tough talk on industry Jan 11 2017
New Strong Buy Stocks for January 5th Jan 05 2017
United Therapeutics Corporation To Present At 35th Annual J.P. Morgan Healthcare Conference Jan 05 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)